CHARLES M. BAUM - 22 Jun 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
28 Jun 2023, 17:06:17 UTC
Previous filing
16 Jun 2023
Next filing
10 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +32,500 $0.000000 32,500 22 Jun 2023 Common Stock 32,500 $12.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in 36 substantially equal monthly installments beginning on June 22, 2023 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.